Leader of government’s national scheme for obesity treatments was paid nearly {pound}80 000 by GLP-1 drug firms

Coverage, in order

1. 15d ago
   The BMJ UK indie study peer-reviewed

   Leader of government’s national scheme for obesity treatments was paid nearly {pound}80 000 by GLP-1 drug firms

   The head of the UK government’s national scheme to test new obesity treatments has received nearly £80 000 from the makers of the glucagon-like peptide-1 (GLP-1) receptor agonists semaglutide (Wegovy) and tirzepatide (Mounjaro), The BMJ can reveal.Since 2021 Naveed Sattar has been paid a total of…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.